Skip to main content
Terug
CAMRF logo

Camurus AB (publ)

Datakwaliteit: 100%
Oversold
CAMRF
OTC Healthcare Biotechnology
€ 55,00
€ 0,00 (0,00%)
Marktkapitalisatie: 3,28B
Dagbereik
€ 55,00 € 55,00
52-Weeksbereik
€ 52,31 € 71,07
Volume
100
50D / 200D Gem.
€ 63,01 / € 66,31
Vorige Slotkoers
€ 55,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 4,5 0,4
P/B 0,8 2,9
ROE % 19,6 3,7
Net Margin % 32,5 3,9
Rev Growth 5Y % 39,4 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 75,60
€ 63,95 – € 96,52
 12 B 1
FY2029 € 58,70
€ 49,66 – € 74,95
 8,4 B 1
FY2028 € 46,97
€ 39,73 – € 59,97
 6,3 B 1

Belangrijkste Punten

Revenue grew 39,36% annually over 5 years — strong growth
Earnings grew 71,70% over the past year
ROE of 19,55% — decent returns on equity
Net margin of 32,47% shows strong profitability
Debt/Equity of 0,03 — conservative balance sheet
Generating 730,78M in free cash flow

Groei

Revenue Growth (5Y)
39,36%
Revenue (1Y)21,30%
Earnings (1Y)71,70%
FCF Growth (3Y)10,66%

Kwaliteit

Return on Equity
19,55%
ROIC15,10%
Net Margin32,47%
Op. Margin38,58%

Veiligheid

Debt / Equity
0,03
Current Ratio12,09
Interest Coverage151,78

Waardering

P/E Ratio
4,46
P/B Ratio0,78
EV/EBITDA-0,39
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,30% Revenue Growth (3Y) 14,87%
Earnings Growth (1Y) 71,70% Earnings Growth (3Y) 30,57%
Revenue Growth (5Y) 39,36% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,27B Net Income (TTM) 735,57M
ROE 19,55% ROA 15,52%
Gross Margin 93,11% Operating Margin 38,58%
Net Margin 32,47% Free Cash Flow (TTM) 730,78M
ROIC 15,10% FCF Growth (3Y) 10,66%
Safety
Debt / Equity 0,03 Current Ratio 12,09
Interest Coverage 151,78 Dividend Yield 0,00%
Valuation
P/E Ratio 4,46 P/B Ratio 0,78
P/S Ratio 1,45 PEG Ratio 0,73
EV/EBITDA -0,39 Dividend Yield 0,00%
Market Cap 3,28B Enterprise Value -336,73M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,27B 1,87B 1,72B 956,34M 600,57M
Net Income 735,57M 428,39M 431,44M 55,55M -90,45M
EPS (Diluted) 12,26 7,20 7,50 1,01 -1,66
Gross Profit 2,11B 1,74B 1,59B 853,08M 515,22M
Operating Income 873,93M 469,17M 525,90M 71,96M -110,57M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,74B 3,76B 1,91B 1,31B 1,08B
Total Liabilities 504,56M 467,33M 414,82M 310,82M 232,99M
Shareholders' Equity 4,24B 3,29B 1,49B 994,67M 848,91M
Total Debt 106,03M 17,04M 24,51M 26,22M 25,66M
Cash & Equivalents 3,73B 2,85B 1,19B 565,54M 411,58M
Current Assets 4,44B 3,55B 1,62B 915,35M 679,30M
Current Liabilities 367,17M 438,63M 368,59M 281,64M 213,05M

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#742 of 1024
34
Custom Capital Light Compounder
#38 of 213
56
Custom Deep Value Investing (Seth Klarman)
#693 of 820
24
Custom Contrarian Investing (David Dreman)
#211 of 658
43
Value Defensive Investing (Benjamin Graham)
#145 of 708
48
Custom Full Throttle
#78 of 146
44
Custom Lower Risk
#67 of 136
46

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026